<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34942461</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-1705</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>103</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>International immunopharmacology</Title>
          <ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Levocetirizine and montelukast in the COVID-19 treatment paradigm.</ArticleTitle>
        <Pagination>
          <StartPage>108412</StartPage>
          <MedlinePgn>108412</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2021.108412</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1567-5769(21)01048-1</ELocationID>
        <Abstract>
          <AbstractText>Levocetirizine, a third-generation antihistamine, and montelukast, a leukotriene receptor antagonist, exhibit remarkable synergistic anti-inflammatory activity across a spectrum of signaling proteins, cell adhesion molecules, and leukocytes. By targeting cellular protein activity, they are uniquely positioned to treat the symptoms of COVID-19. Clinical data to date with an associated six-month follow-up, suggests the combination therapy may prevent the progression of the disease from mild to moderate to severe, as well as prevent/treat many of the aspects of 'Long COVID,' thereby cost effectively reducing both morbidity and mortality. To investigate patient outcomes, 53 consecutive COVID-19 test (+) cases (ages 3-90) from a well-established, single-center practice in Boston, Massachusetts, between March - November 2020, were treated with levocetirizine and montelukast in addition to then existing protocols [2]. The data set was retrospectively reviewed. Thirty-four cases were considered mild (64%), 17 moderate (32%), and 2 (4%) severe. Several patients presented with significant comorbidities (obesity: n = 22, 41%; diabetes: n = 10, 19%; hypertension: n = 24, 45%). Among the cohort there were no exclusions, no intubations, and no deaths. The pilot study in Massachusetts encompassed the first COVID-19 wave which peaked on April 23, 2020 as well as the ascending portion of the second wave in the fall. During this period the average weekly COVID-19 case mortality rate (confirmed deaths/confirmed cases) varied considerably between 1 and 7.5% [37]. FDA has approved a multicenter, randomized, placebo-controlled, Phase 2 clinical trial design, replete with electronic diaries and laboratory metrics to explore scientific questions not addressed herein.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>May</LastName>
            <ForeName>Bruce Chandler</ForeName>
            <Initials>BC</Initials>
            <AffiliationInfo>
              <Affiliation>Inflammatory Response Research, Inc., 515 E. Micheltorena, Suite G, Santa Barbara, CA 93103, United States; Otolaryngology, Head &amp; Neck Surgery, Cottage Health, 400 West Pueblo Street, Santa Barbara, CA 93105, United States. Electronic address: bcmay@irrinc.net.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gallivan</LastName>
            <ForeName>Kathleen Holly</ForeName>
            <Initials>KH</Initials>
            <AffiliationInfo>
              <Affiliation>Otolaryngology, Head &amp; Neck Surgery, 100 Unicorn Park, Suite 102, Woburn, MA 01801, United States. Electronic address: kathleen_gallivan@meei.Harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int Immunopharmacol</MedlineTA>
        <NlmUniqueID>100965259</NlmUniqueID>
        <ISSNLinking>1567-5769</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003521">Cyclopropanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D039563">Histamine H1 Antagonists, Non-Sedating</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020024">Leukotriene Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013440">Sulfides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6U5EA9RT2O</RegistryNumber>
          <NameOfSubstance UI="C472067">levocetirizine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>MHM278SD3E</RegistryNumber>
          <NameOfSubstance UI="C093875">montelukast</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YO7261ME24</RegistryNumber>
          <NameOfSubstance UI="D017332">Cetirizine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017332" MajorTopicYN="N">Cetirizine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003521" MajorTopicYN="N">Cyclopropanes</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D039563" MajorTopicYN="N">Histamine H1 Antagonists, Non-Sedating</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020024" MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013440" MajorTopicYN="N">Sulfides</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-inflammatory</Keyword>
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Levocetirizine</Keyword>
        <Keyword MajorTopicYN="N">Long COVID</Keyword>
        <Keyword MajorTopicYN="N">Montelukast</Keyword>
        <Keyword MajorTopicYN="N">Therapeutic</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: B. Chandler May, MD, JD, MS, FCLM is a practicing physician and CEO of Inflammatory Response Research, Inc. (IRR, Inc.) a drug development company focused on the combination of levocetirizine and montelukast for the treatment of inflammatory disorders. The current retrospective study utilized commercially available levocetirizine and montelukast from sources unrelated to IRR, Inc; independently prescribed by Kathleen Holly Gallivan, MD, MPH, FACS, FAAOA. Dr. Gallivan has no financial interests to report.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>23</Day>
          <Hour>20</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34942461</ArticleId>
        <ArticleId IdType="pmc">PMC8673734</ArticleId>
        <ArticleId IdType="doi">10.1016/j.intimp.2021.108412</ArticleId>
        <ArticleId IdType="pii">S1567-5769(21)01048-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N. Engl. J. Med. 2005;353(16):1711–1723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16236742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hospital MG. SARS-COV-2 Infection Statuses and Resolution COVID-19, CoV-Presumed, CoV-Risk, and CoV-Exposed. June 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen J., Qi T., Liu L.i., Ling Y., Qian Z., Li T., Li F., Xu Q., Zhang Y., Xu S., Song Z., Zeng Y., Shen Y., Shi Y., Zhu T., Lu H. Clinical progression of patients with COVID-19 in Shanghai, China. J. Infect. 2020;80(5):e1–e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7102530</ArticleId>
            <ArticleId IdType="pubmed">32171869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Morales A.-J.-C.-O.-J., Gutierrez-Ocampo E. Clincial, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med. Infect. Dis. 2020;34:1–13.</Citation>
        </Reference>
        <Reference>
          <Citation>Lauer S.A., Grantz K.H., Bi Q., Jones F.K., Zheng Q., Meredith H.R., Azman A.S., Reich N.G., Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann. Intern. Med. 2020;172(9):577–582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7081172</ArticleId>
            <ArticleId IdType="pubmed">32150748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merad M., Martin J.C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 2020;20(6):355–362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7201395</ArticleId>
            <ArticleId IdType="pubmed">32376901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fahmi A.N.A.S.G., Salem H.A. Levocetirizine pretreatment mitigates lipopolysaccharide-induced lung inflammation in rats. Biomed Res. Int. 2018;2018:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6110004</ArticleId>
            <ArticleId IdType="pubmed">30186866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogli S., Stefanelli F., Neri T., Bardelli C., Amoruso A., Brunelleschi S., Celi A., Breschi M.C. Montelukast prevents microparticle-induced inflammatory and functional alterations in human bronchial smooth muscle cells. Pharmacol. Res. 2013;76:149–156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23954527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giustizieri M.L., Albanesi C., Fluhr J., Gisondi P., Norgauer J., Girolomoni G. H1 histamine receptor mediates inflammatory responses in human keratinocytes. J. Allergy Clin. Immunol. 2004;114(5):1176–1182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15536428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hair P.I., Scott L.J. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs. 2006;66(7):973–996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16740020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang Y.J., Wang J.H., Kim J.S., Kwon H.J., Yeo N.-K., Lee B.-J. Levocetirizine inhibits rhinovirus-induced ICAM-1 and cytokine expression and viral replication in airway epithelial cells. Antiviral Res. 2009;81(3):226–233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19110001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mullol J., Callejas F.B., Méndez-Arancibia E., et al.  Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. J. Biol. Regul. Homeost. Agents. 2010;24(4):403–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21122279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peters-Golden M., Henderson W.R. Leukotrienes. N. Engl. J. Med. 2007;357(18):1841–1854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17978293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson A.J., Kashanin D., O'Dowd F., Williams V., Walsh G.M. Montelukast inhibition of resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of cysLT(1)R antagonism. J. Leukoc. Biol. 2008;83(6):1522–1529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18332235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stelmach I., Jerzynska J., Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J. Allergy Clin. Immunol. 2002;109(2):257–263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11842294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tahan F., Jazrawi E., Moodley T., Rovati G.E., Adcock I.M. Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity. Clin. Exp. Allergy. 2008;38(5):805–811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18325031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theron A.J., Steel H.C., Tintinger G.R., Gravett C.M., Anderson R., Feldman C. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res. 2014;2014:1–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4058211</ArticleId>
            <ArticleId IdType="pubmed">24971371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tintinger G.R., Feldman C., Theron A.J., Anderson R. Montelukast: more than a cysteinyl leukotriene receptor antagonist? Sci. World J. 2010;10:2403–2413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5763941</ArticleId>
            <ArticleId IdType="pubmed">21170491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>www.bu.edu/NF-kB. NF-kB. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>DeDiego M.L., Nieto-Torres J.L., Regla-Nava J.A., et al.  Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J. Virol. 2014;88(2):913–924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3911641</ArticleId>
            <ArticleId IdType="pubmed">24198408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roumestan C., Henriquet C., Gougat C., Michel A., Bichon F., Portet K., Jaffuel D., Mathieu M. Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin. Exp. Allergy. 2008;38(6):947–956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18498541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S.M.Q. Ying, A.B. Kay, The effect of levocetirizine on histamine and cytokine-induced upregulation of eotaxin by endothelial cells, in: Proceedings of the XXI Congress of the European Academy of Allergy and Clincial Immunology; 2001; Naples, France; 2001.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr. Med. Chem. 2008;15(21):2173–2191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18781943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Church M.K., Church D.S. Pharmacology of antihistamines. Indian J. Dermatol. 2013;58(3):219–224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3667286</ArticleId>
            <ArticleId IdType="pubmed">23723474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estelle F., Simons R., Mcmillan J., Simons K. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J. Allergy Clin. Immunol. 1990;86(4):540–547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1977781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gillman S., Gillard M., Benedetti M.S. The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistamines. Allergy Asthma Proc. 2009;30(4):366–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19335943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grant J.A., Riethuisen J.-M., Moulaert B., DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann. Allergy Asthma Immunol. 2002;88(2):190–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11868924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davino-Chiovatto J.E., Oliveira-Junior M.C., MacKenzie BreAnne, Santos-Dias A., Almeida-Oliveira A.R., Aquino-Junior J.C.J., Brito A.A., Rigonato-Oliveira N.C., Damaceno-Rodrigues N.R., Oliveira A.P.L., Silva A.P., Consolim-Colombo F.M., Aimbire F., Castro-Faria-Neto H.C., Vieira R.P. Montelukast, leukotriene inhibitor, reduces LPS-induced acute lung inflammation and human neutrophil activation. Arch. Bronconeumol. 2019;55(11):573–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31257011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suetrong B. Successful treatment of refractory pediatric severe ARDS with high-dose montelukast. Crit. Care Med. 2019;47(1):1244.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Saleh A.-A., Awad I.E., Yadav A., Poirier R.A. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations. PCCP. 2020;22(40):23099–23106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33025993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar S., Singh B., Kumari P., Kumar P.V., Agnihotri G., Khan S., Kant Beuria T., Syed G.H., Dixit A. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity. Comput. Struct. Biotechnol. J. 2021;19:1998–2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8025584</ArticleId>
            <ArticleId IdType="pubmed">33841751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Štekláč M., Zajaček D., Bučinský L. 3CL(pro) and PL(pro) affinity, a docking study to fight COVID19 based on 900 compounds from PubChem and literature. Are there new drugs to be found? J. Mol. Struct. 2021;1245:130968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8238401</ArticleId>
            <ArticleId IdType="pubmed">34219808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Copertino D.C., Duarte R.R.R., Powell T.R., Mulder Rougvie M., Nixon D.F. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) J. Med. Virol. 2021;93(1):187–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7405283</ArticleId>
            <ArticleId IdType="pubmed">32658304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S. Durdagi, T. Avsar, M.D. Orhan, et al., The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies, Molecular Therapy 2021 Oct 19;S1525-0016(21)00521-9. Online ahead of print.</Citation>
        </Reference>
        <Reference>
          <Citation>Sansing-Foster V. Neuropsychiatric adverse events and montelukast: observational safety analyses. FDA. 2019:1–37.</Citation>
        </Reference>
        <Reference>
          <Citation>Ali M.M., O'Brien C.E., Cleves M.A., Martin B.C. Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case-control study. Pharmacoepidemiol. Drug Saf. 2015;24(4):435–445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25683909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philip G., Hustad C.M., Malice M.-P., Noonan G., Ezekowitz A., Reiss T.F., Knorr B. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J. Allergy Clin. Immunol. 2009;124(4):699–706.e8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19815116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumock G.T., Stayner L.T., Valuck R.J., Joo M.J., Gibbons R.D., Lee T.A. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study. J. Allergy Clin. Immunol. 2012;130(2):368–375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22698520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachert C., Bousquet J., Canonica G.W., Durham S.R., Klimek L., Mullol J., Van Cauwenberge P.B., Van Hammée G. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J. Allergy Clin. Immunol. 2004;114(4):838–844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15480324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroenke K., Spitzer R.L., Williams J.B., Lowe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50(6):613–621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19996233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanofi. XYZAL Prescribing Information, vol. 19, 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharma V.K., Gupta V., Pathak M., Ramam M. An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose. J. Dermatolog. Treat. 2017;28(6):539–543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27779432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dyall J., Coleman C.M., Hart B.J., Venkataraman T., Holbrook M.R., Kindrachuk J., Johnson R.F., Olinger G.G., Jahrling P.B., Laidlaw M., Johansen L.M., Lear-Rooney C.M., Glass P.J., Hensley L.E., Frieman M.B. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 2014;58(8):4885–4893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4136000</ArticleId>
            <ArticleId IdType="pubmed">24841273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain R.K. Cetirizine and astemizole in allergic rhinitis a comparative study. Indian J. Otolaryngol. Head Neck Surg. 1999;51(3):94–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3451055</ArticleId>
            <ArticleId IdType="pubmed">23119559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z., Vorperian V.R., Gong Q., Zhang S., January C.T. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J. Cardiovasc. Electrophysiol. 1999;10(6):836–843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10376921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merck. Singulair Prescribing Information, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Storms W., Michele T.M., Knorr B., et al.  Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged &gt; or = 6 years. Clin. Exp. Allergy. 2001;31(1):77–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11167954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarzi-Puttini P., Giorgi V., Sirotti S., et al.  COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin. Exp. Rheumatol. 2020;38(2):337–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32202240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Li Y., Wang X., Zou P. Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity. Front. Microbiol. 2019;10:3079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7002393</ArticleId>
            <ArticleId IdType="pubmed">32082265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gandon J.M., Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br. J. Clin. Pharmacol. 2002;54(1):51–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1874390</ArticleId>
            <ArticleId IdType="pubmed">12100225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tillement Jean-Paul, Testa Bernard, Brée Françoise. Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem. Pharmacol. 2003;66(7):1123–1126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14505791</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
